Development of early life gut resistome and mobilome across gestational ages and microbiota-modifying treatments

Background - Gestational age (GA) and associated level of gastrointestinal tract maturation are major factors driving the initial gut microbiota composition in preterm infants. Besides, compared to term infants, premature infants often receive antibiotics to treat infections and probiotics to restor...

Full description

Bibliographic Details
Published in:eBioMedicine
Main Authors: Bargheet, Ahmed, Klingenberg, Claus Andreas, Esaiassen, Eirin, Hjerde, Erik, Cavanagh, Jorunn Pauline, Bengtsson-Palme, Johan, Pettersen, Veronika K.
Format: Article in Journal/Newspaper
Language:English
Published: Elsevier 2023
Subjects:
Online Access:https://hdl.handle.net/10037/30066
https://doi.org/10.1016/j.ebiom.2023.104613
id ftunivtroemsoe:oai:munin.uit.no:10037/30066
record_format openpolar
spelling ftunivtroemsoe:oai:munin.uit.no:10037/30066 2023-09-05T13:21:57+02:00 Development of early life gut resistome and mobilome across gestational ages and microbiota-modifying treatments Bargheet, Ahmed Klingenberg, Claus Andreas Esaiassen, Eirin Hjerde, Erik Cavanagh, Jorunn Pauline Bengtsson-Palme, Johan Pettersen, Veronika K. 2023-05-13 https://hdl.handle.net/10037/30066 https://doi.org/10.1016/j.ebiom.2023.104613 eng eng Elsevier EBioMedicine Sigma2: NN8021K Tromsø forskningsstiftelse: 18_CANS_AS Bargheet, Klingenberg, Esaiassen, Hjerde, Cavanagh, Bengtsson-Palme, Pettersen. Development of early life gut resistome and mobilome across gestational ages and microbiota-modifying treatments. EBioMedicine. 2023;92 FRIDAID 2151471 doi:10.1016/j.ebiom.2023.104613 2352-3964 https://hdl.handle.net/10037/30066 Attribution 4.0 International (CC BY 4.0) openAccess Copyright 2023 The Author(s) https://creativecommons.org/licenses/by/4.0 Journal article Tidsskriftartikkel Peer reviewed publishedVersion 2023 ftunivtroemsoe https://doi.org/10.1016/j.ebiom.2023.104613 2023-08-23T23:07:13Z Background - Gestational age (GA) and associated level of gastrointestinal tract maturation are major factors driving the initial gut microbiota composition in preterm infants. Besides, compared to term infants, premature infants often receive antibiotics to treat infections and probiotics to restore optimal gut microbiota. How GA, antibiotics, and probiotics modulate the microbiota’s core characteristics, gut resistome and mobilome, remains nascent. Methods - We analysed metagenomic data from a longitudinal observational study in six Norwegian neonatal intensive care units to describe the bacterial microbiota of infants of varying GA and receiving different treatments. The cohort consisted of probiotic-supplemented and antibiotic-exposed extremely preterm infants (n = 29), antibiotic-exposed very preterm (n = 25), antibiotic-unexposed very preterm (n = 8), and antibiotic-unexposed full-term (n = 10) infants. The stool samples were collected on days of life 7, 28, 120, and 365, and DNA extraction was followed by shotgun metagenome sequencing and bioinformatical analysis. Findings - The top predictors of microbiota maturation were hospitalisation length and GA. Probiotic administration rendered the gut microbiota and resistome of extremely preterm infants more alike to term infants on day 7 and ameliorated GA-driven loss of microbiota interconnectivity and stability. GA, hospitalisation, and both microbiota-modifying treatments (antibiotics and probiotics) contributed to an elevated carriage of mobile genetic elements in preterm infants compared to term controls. Finally, Escherichia coli was associated with the highest number of antibiotic-resistance genes, followed by Klebsiella pneumoniae and Klebsiella aerogenes. Interpretation - Prolonged hospitalisation, antibiotics, and probiotic intervention contribute to dynamic alterations in resistome and mobilome, gut microbiota characteristics relevant to infection risk. Funding - Odd-Berg Group, Northern Norway Regional Health Authority. Article in Journal/Newspaper Northern Norway University of Tromsø: Munin Open Research Archive Norway eBioMedicine 92 104613
institution Open Polar
collection University of Tromsø: Munin Open Research Archive
op_collection_id ftunivtroemsoe
language English
description Background - Gestational age (GA) and associated level of gastrointestinal tract maturation are major factors driving the initial gut microbiota composition in preterm infants. Besides, compared to term infants, premature infants often receive antibiotics to treat infections and probiotics to restore optimal gut microbiota. How GA, antibiotics, and probiotics modulate the microbiota’s core characteristics, gut resistome and mobilome, remains nascent. Methods - We analysed metagenomic data from a longitudinal observational study in six Norwegian neonatal intensive care units to describe the bacterial microbiota of infants of varying GA and receiving different treatments. The cohort consisted of probiotic-supplemented and antibiotic-exposed extremely preterm infants (n = 29), antibiotic-exposed very preterm (n = 25), antibiotic-unexposed very preterm (n = 8), and antibiotic-unexposed full-term (n = 10) infants. The stool samples were collected on days of life 7, 28, 120, and 365, and DNA extraction was followed by shotgun metagenome sequencing and bioinformatical analysis. Findings - The top predictors of microbiota maturation were hospitalisation length and GA. Probiotic administration rendered the gut microbiota and resistome of extremely preterm infants more alike to term infants on day 7 and ameliorated GA-driven loss of microbiota interconnectivity and stability. GA, hospitalisation, and both microbiota-modifying treatments (antibiotics and probiotics) contributed to an elevated carriage of mobile genetic elements in preterm infants compared to term controls. Finally, Escherichia coli was associated with the highest number of antibiotic-resistance genes, followed by Klebsiella pneumoniae and Klebsiella aerogenes. Interpretation - Prolonged hospitalisation, antibiotics, and probiotic intervention contribute to dynamic alterations in resistome and mobilome, gut microbiota characteristics relevant to infection risk. Funding - Odd-Berg Group, Northern Norway Regional Health Authority.
format Article in Journal/Newspaper
author Bargheet, Ahmed
Klingenberg, Claus Andreas
Esaiassen, Eirin
Hjerde, Erik
Cavanagh, Jorunn Pauline
Bengtsson-Palme, Johan
Pettersen, Veronika K.
spellingShingle Bargheet, Ahmed
Klingenberg, Claus Andreas
Esaiassen, Eirin
Hjerde, Erik
Cavanagh, Jorunn Pauline
Bengtsson-Palme, Johan
Pettersen, Veronika K.
Development of early life gut resistome and mobilome across gestational ages and microbiota-modifying treatments
author_facet Bargheet, Ahmed
Klingenberg, Claus Andreas
Esaiassen, Eirin
Hjerde, Erik
Cavanagh, Jorunn Pauline
Bengtsson-Palme, Johan
Pettersen, Veronika K.
author_sort Bargheet, Ahmed
title Development of early life gut resistome and mobilome across gestational ages and microbiota-modifying treatments
title_short Development of early life gut resistome and mobilome across gestational ages and microbiota-modifying treatments
title_full Development of early life gut resistome and mobilome across gestational ages and microbiota-modifying treatments
title_fullStr Development of early life gut resistome and mobilome across gestational ages and microbiota-modifying treatments
title_full_unstemmed Development of early life gut resistome and mobilome across gestational ages and microbiota-modifying treatments
title_sort development of early life gut resistome and mobilome across gestational ages and microbiota-modifying treatments
publisher Elsevier
publishDate 2023
url https://hdl.handle.net/10037/30066
https://doi.org/10.1016/j.ebiom.2023.104613
geographic Norway
geographic_facet Norway
genre Northern Norway
genre_facet Northern Norway
op_relation EBioMedicine
Sigma2: NN8021K
Tromsø forskningsstiftelse: 18_CANS_AS
Bargheet, Klingenberg, Esaiassen, Hjerde, Cavanagh, Bengtsson-Palme, Pettersen. Development of early life gut resistome and mobilome across gestational ages and microbiota-modifying treatments. EBioMedicine. 2023;92
FRIDAID 2151471
doi:10.1016/j.ebiom.2023.104613
2352-3964
https://hdl.handle.net/10037/30066
op_rights Attribution 4.0 International (CC BY 4.0)
openAccess
Copyright 2023 The Author(s)
https://creativecommons.org/licenses/by/4.0
op_doi https://doi.org/10.1016/j.ebiom.2023.104613
container_title eBioMedicine
container_volume 92
container_start_page 104613
_version_ 1776202510832238592